Mosunetuzumab monotherapy is an effective and well-tolerated treatment option for patients with relapsed/refractory (R/R) follicular lymphoma (FL) who have received ≥2 prior lines of therapy: Pivotal results from a phase I/II study Meeting Abstract
| Authors: | Budde, E. L.; Sehn, L. H.; Matasar, M.; Schuster, S. J.; Assouline, S.; Giri, P.; Kuruvilla, J.; Canales, M.; Dietrich, S.; Fay, K.; Ku, M.; Nastoupil, L.; Wei, M. C.; Yin, S.; Doral, M. Y.; Li, C. C.; Huang, H.; Negricea, R.; Penuel, E.; O'Hear, C.; Bartlett, N. L. |
| Abstract Title: | Mosunetuzumab monotherapy is an effective and well-tolerated treatment option for patients with relapsed/refractory (R/R) follicular lymphoma (FL) who have received ≥2 prior lines of therapy: Pivotal results from a phase I/II study |
| Meeting Title: | 10th Annual Meeting of the Society of Hematologic Oncology (SOHO) |
| Keywords: | follicular lymphoma; antibody; relapsed/refractory; phase i/ii; bispecific; ibcl; mosunetuzumab |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 22 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2022 Sep 28-Oct 1 |
| Meeting Location: | Houston, TX |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2022-10-01 |
| Start Page: | S387 |
| Language: | English |
| ACCESSION: | WOS:000897948100433 |
| PROVIDER: | wos |
| DOI: | 10.1016/s2152-2650(22)01554-3 |
| Notes: | Meeting Abstract: IBCL-249 -- Source: Wos |
